Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 12
2007 1
2009 1
2012 2
2013 1
2014 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 21290683

18 results

Results by year

Filters applied: . Clear all
Page 1
Fabry Disease: Perspectives from 5 Years of FOS.
Mehta A, Beck M, Sunder-Plassmann G, editors. Mehta A, editor, et al. Oxford: Oxford PharmaGenesis; 2006. Oxford: Oxford PharmaGenesis; 2006. PMID: 21290683 Free Books & Documents. Review.
Effect of enzyme replacement therapy with agalsidase alfa on renal function in patients with Fabry disease: data from FOS – the Fabry Outcome Survey.
Schwarting A, Sunder-Plassmann G, Mehta A, Beck M. Schwarting A, et al. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 38. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 38. PMID: 21290680 Free Books & Documents. Review.
Natural history and effects of enzyme replacement therapy in children and adolescents with Fabry disease.
Ramaswami U, Parini R, Pintos-Morell G. Ramaswami U, et al. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 31. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 31. PMID: 21290674 Free Books & Documents. Review.
Effects of enzyme replacement therapy on pain and overall quality of life.
Hoffmann B. Hoffmann B. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 40. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 40. PMID: 21290678 Free Books & Documents. Review.
Formal trials versus observational studies.
Thadhani R. Thadhani R. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 14. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 14. PMID: 21290694 Free Books & Documents. Review.
Fabry disease in females: clinical characteristics and effects of enzyme replacement therapy.
Deegan PB, Bähner F, Barba M, Hughes DA, Beck M. Deegan PB, et al. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 30. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 30. PMID: 21290688 Free Books & Documents. Review.
Organization and technical aspects of FOS – the Fabry Outcome Survey.
Hernberg-Ståhl E. Hernberg-Ståhl E. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 15. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 15. PMID: 21290693 Free Books & Documents. Review.
Development of enzyme replacement therapy for Fabry disease.
Schiffmann R, Brady RO. Schiffmann R, et al. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 36. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 36. PMID: 21290704 Free Books & Documents. Review.
18 results